Antiprotozoal medications associated with increased longevity and reduced morbidity in two national cohorts

Running Title: Antiprotozoal medications and longevity

Ariel Israel[1,2]* MD, PhD, Abraham Weizman MD[3], Sarah Israel MD[4], Shai Ashkenazi MD, MSc[5,6], Eytan Ruppin MD, PhD[7], Shlomo Vinker MD, MHA[1], Eli Magen MD[8], Eugene Merzon MD, MPH[1,5]

Affiliations:

[1] Department of Epidemiology and Preventive Medicine, School of Public Health, Gray Faculty of Medical & Health Sciences, Tel Aviv University; Ramat Aviv, Tel Aviv 6997801, Israel

[2] Leumit Research Institute, Leumit Health Services, 23 Sprinzak St., Tel Aviv 6473817, Israel

[3] Research Unit, Geha Mental Health Center, Felsenstein Medical Research Center, and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel Aviv University, 6997801, Israel

[4] Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, P.O. Box 12000, Jerusalem 9112001, Israel

[5] Adelson School of Medicine, Ariel University, Ariel 40700, Israel

[6] Department of Infectious Diseases, Schneider Children's Medical Center, 14 Kaplan St., Petah Tikva 4920235, Israel

[7] Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

[8] Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Derech HaRofe 7, Ashdod 7747629, Israel

Corresponding author: Ariel Israel, Leumit Research Institute, Sprinzak 23, Tel-Aviv 6473817, Israel, Telephone: +972-3-6970483. Fax: +972-76-8889190

Email: aisrael@leumit.co.il

Word count: 5480

Tables count: 3

Figures count: 4

Abstract

We conducted a stepwise pharmacoepidemiologic investigation, an unbiased medication-wide screen followed by matched cohort validation and external replication, to identify medications associated with longevity and aging-related morbidity. The initial screen, performed in a large national health system, identified two antiprotozoals, atovaquone-proguanil and mefloquine, as being associated with increased survival. Matched exposed-unexposed cohorts were then constructed to validate mortality associations and examine incident outcomes, revealing reduced risks for diabetes, dementia, cardiovascular, renal, hepatic, pulmonary, and selected cancers, alongside increased risks for hearing loss, dry eye/Sjogren's, and lichen planus. These patterns were externally replicated in the US TriNetX network, where similar associations were observed for atovaquone-proguanil, mefloquine, and nirmatrelvir-ritonavir. Because nirmatrelvir-ritonavir is prescribed to older, multimorbid individuals, its associations are unlikely to reflect healthy-traveler conditioning. The concordant protective and tissue-specific adverse associations across datasets and antiprotozoal drug classes support a testable hypothesis: short antiprotozoal courses may reduce aging-related morbidity by decreasing persistent protozoal burden, particularly *Toxoplasma gondii*.

Keywords: Aging; Longevity; Pharmacoepidemiology; Antiprotozoal agents; *Toxoplasma gondii*; Mortality; Drug repurposing

Introduction

Identifying the long-term effects of medications is a central goal of pharmacoepidemiology and drug repurposing research. Many approved drugs may exert previously unrecognized influences on human health, with potential benefits or harms extending beyond their original indications. Medications that promote healthy aging would be expected to reduce mortality and lower the incidence of chronic disease.

Electronic health records (EHRs) from large healthcare organizations offer a powerful resource for systematically evaluating the long-term effects of medications on mortality and age-related morbidity [1–3]. Using EHR data from Leumit Health Services (LHS), a nationwide provider in Israel, we performed a medication-wide exploratory screen to identify drugs associated with increased longevity. This discovery analysis highlighted two antiprotozoal agents, atovaquone-proguanil and mefloquine, both primarily prescribed for malaria prophylaxis in travelers. These medications have not previously been implicated in long-term survival or aging-related morbidity. Their emergence from an unbiased, medication-wide screen motivated the targeted evaluation of these medications, which were selected to address an apparent knowledge gap rather than through hypothesis-driven preselection.

The identification of antiprotozoal medications as longevity-associated agents is consistent with emerging evidence linking the human microbiome to age-related diseases, including cardiovascular [4], metabolic [5], malignant [6] and neurodegenerative disorders [7,8]. Antiprotozoal agents may modulate the microbiome—particularly through elimination of specific protozoal pathogens—and thereby influence long-term health outcomes beyond their original therapeutic purposes.

To explore and validate these findings, we undertook a sequence of follow-up analyses. In LHS, we constructed matched exposed-unexposed cohorts to validate mortality associations and to examine the incidence of common age-related conditions in the decade following the first uptake of antiprotozoal

medications. We then sought external validation in the US-based TriNetX federated network,

comprising EHR data from more than 120 million individuals. There, we examined atovaquone-

proguanil and mefloquine, prescribed mainly for malaria prophylaxis in travelers, alongside

nirmatrelvir-ritonavir, an antiviral used in older and comorbid patients at risk for COVID-19

complications that also has antiprotozoal activity. Inclusion of this latter cohort helped address potential

"healthy traveler" bias by confirming that protective associations extend to non-traveler populations.

Across these analyses, we observed consistent associations between antiprotozoal exposure and reduced

mortality, accompanied by concordant changes in the incidence of multiple age-related diseases.

Figure 1 summarizes the study design, which comprised three sequential analyses: a discovery

screen in LHS (Analysis A), a validation-exploration cohort in LHS (Analysis B), and external

validation in TriNetX (Analysis C).

Results

Analysis A: LHS exploratory cohort

Table 1 summarizes the demographic and clinical characteristics of 14,986 patients who died

before the cohort median age of death (cases) and 14,986 matched survivors (controls) in the LHS

cohort. Matching ensured similar distributions of age, sex, and socioeconomic status (49.2% female,

mean age 71.0 ± 5.9 years at index). Compared to controls, cases had slightly higher BMI (29.1 ± 6.0 vs.

28.5 ± 4.8 kg/m²) and weight (77.5 ± 17.7 vs. 76.3 ± 14.6 kg) and were more likely to be smokers (OR

2.00, 95% CI 1.86-2.15). After an average follow-up of 12.5 years, controls reached a mean age of 83.6

± 5.9 years, while cases died at a mean age of 74.3 ± 5.7 years (Table 1B).

Analysis A results: Medications associated with decreased mortality

Medication use during the preceding decade was systematically evaluated for associations with mortality. Out of 1470 screened compounds, seven agents, from diverse therapeutic classes met the prespecified OR and FDR threshold (OR<0.5, FDR <0.5%, Benjamini-Hochberg correction). The ATC class P01B (antimalarials) was the only therapeutic category represented by multiple top entries, prompting downstream validation of these two antiprotozoal agents: mefloquine (OR 0.32, 95% CI 0.15–0.65, FDR = 0.0001) and atovaquone–proguanil (OR 0.43, 95% CI 0.27–0.69, FDR = 0.0002) (Supplementary Table 1).

Analysis B: Validation-Exploration Cohort in LHS

These findings prompted a more detailed evaluation of mortality and morbidity outcomes in matched cohorts. We constructed a cohort of individuals aged 40-85 who had received at least one prescription for either A-P or mefloquine, and matched each treated patient to 20 unexposed controls based on sex, socioeconomic status (SES), and year of first EHR record. The final cohort included 3,876 treated individuals and 77,820 controls with broadly comparable baseline characteristics (Table 2).

The mean age at index date was 56.3 years in both groups, with 52.3% female participants. Small but statistically significant baseline differences were noted for BMI (27.0 ± 4.5 vs. 27.5 ± 5.2 kg/m², $p < 0.001$), weight (76.3 ± 15.3 vs. 77.3 ± 16.5 kg, $p < 0.001$), and height (168 ± 9 vs. 167 ± 10 cm, $p < 0.001$). Systolic blood pressure was similar across groups, while diastolic blood pressure was slightly lower among treated individuals (76.8 ± 10.1 vs. 77.5 ± 9.0 mmHg, $p < 0.001$). Current smoking was significantly less frequent in the treated group (14.5% vs. 21.8%, $p < 0.001$), although past smoking rates and ethnic sector distributions were similar between cases and controls.

Analysis B: Cox proportional hazards models

We next evaluated the association between exposure to A-P or mefloquine and subsequent mortality and morbidity using Cox proportional hazards models (cumulative incidence plots in Figure 2). Treated individuals had markedly reduced risk of all-cause mortality (HR = 0.40 [95% CI, 0.34-0.47], p < 0.001; Figure 2A). Significant reductions were also observed for dementia (HR = 0.52 [0.41-0.67], p < 0.001; Figure 2B), diabetes mellitus (HR = 0.83 [0.75-0.92], p = 0.0006; Figure 2C), heart failure (HR = 0.76 [0.63-0.91], p = 0.006; Figure 2D), myocardial infarction (HR = 0.78 [0.66-0.92], p = 0.003; Figure 2E), hepatic failure (HR = 0.64 [0.43-0.95], p = 0.03; Figure 2F), chronic obstructive pulmonary disease (COPD) (HR = 0.73 [0.62-0.86], p = 0.0002; Figure 2G), gastrointestinal malignancy (HR = 0.70 [0.52-0.96], p = 0.03; Figure 2H), and lung cancer (HR = 0.52 [0.33-0.82], p = 0.004; Figure 2I).

Conversely, treated individuals exhibited significantly increased risks of hearing loss (HR = 1.25 [1.14-1.37], p < 0.001; Figure 2J), Sjögren's disease/eye dryness (HR = 1.25 [1.14-1.38], p < 0.001; Figure 2K), and lichen planus (HR = 1.54 [1.03-2.31], p = 0.03; Figure 2L).

A forest plot summarizing these outcomes (Figure 3) illustrates the broad reductions in mortality and major age-related conditions associated with antiprotozoal exposure, alongside increased risks of specific auditory, ophthalmic, and dermatologic conditions.

Outcomes that demonstrated statistically significant increases or decreases in LHS were retained for evaluation in TriNetX, irrespective of effect direction. These patterns of both reduced and increased risk therefore motivated the specific set of outcomes selected for replication.

Analysis C: Validation cohorts in the US-based TrinetX collaborative network.

To validate the associations observed in the LHS national cohort, we conducted independent analyses in TriNetX, a federated network comprising EHRs from over 70 US healthcare organizations

and more than 120 million patients. Eligible individuals were those born 70–89 years before the cohort

extraction date, corresponding to individuals who would be aged 70–89 at extraction, irrespective of

vital status. Cases were defined as those with a record of the medication of interest, while controls had

no such exposure. Propensity score matching (PSM) was applied to balance groups on age, sex, race,

ethnicity, smoking status, diabetes, BMI, and HbA1c at baseline.

To address potential indication bias stemming from the use of antimalarials primarily in

travelers, we included a third validation cohort exposed to nirmatrelvir-ritonavir (N-R, Paxlovid). This

drug was selected because of its predicted antiprotozoal properties and its widespread prescription as an

antiviral during the COVID-19 pandemic. The N-R cohort offered substantially greater statistical power

than the smaller A-P and mefloquine cohorts; however, follow-up was limited to a maximum of three

years given the recent introduction of this medication, in contrast to the longer observation periods

available for A-P and mefloquine.

The final matched cohorts included 24,498 exposed individuals and 24,498 controls for A-P,

3,400 exposed and 3,400 controls for mefloquine, and 124,681 exposed and 124,681 controls for N-R

(Table 3). Across cohorts, mean age at index was closely matched (69.0 ± 5.8 years for A-P, 67.6 ± 6.2

years for mefloquine, and 75.0 ± 5.5 years for N-R). The close equivalence of both age at index and

current age after matching empirically confirms identical follow-up time windows in exposed and

unexposed groups, supporting the absence of immortal-time and calendar bias. Sex distributions were

balanced (55% female for A-P, 52% for mefloquine, 58% for N-R). Race and ethnicity distributions

were similar within each matched cohort, with the majority identified as White (83% for A-P, 56% for

mefloquine, 85% for N-R). Baseline prevalence of nicotine dependence (3-8%), diabetes mellitus (14-

26%), and overweight/obesity (13-27%) were comparable between groups. HbA1c and BMI were also

closely matched, ensuring well-balanced baseline metabolic profiles for subsequent outcome analyses.

 Analysis C: Cox proportional hazard models

In the TriNetX cohorts, we evaluated mortality and age-related conditions identified in the LHS

analyses, excluding individuals with a prior diagnosis of each outcome at baseline. Cumulative

incidence plots are presented in Figure 4.

Consistent and significant reductions in all-cause mortality were observed across all three

medications: $HR = 0.26$ (95% CI, 0.24-0.28; $p < 0.001$) for A-P, $HR = 0.33$ (0.27-0.40; $p < 0.001$) for

mefloquine, and $HR = 0.50$ (0.48-0.52; $p < 0.001$) for N-R. Significant reductions were found for major

chronic diseases. Dementia incidence was reduced ($HR = 0.48$-0.64 across medications), as were

diabetes mellitus diagnoses ($HR = 0.56$-0.75) and diabetes defined by first occurrence of HbA1c $\geq 6.5\%$

($HR = 0.57$-0.68). Kidney disease, defined as an eGFR < 45 mL/min/1.73 m², was also significantly

reduced ($HR = 0.53$-0.71). Additional reductions were observed for heart failure ($HR = 0.55$-0.75),

myocardial infarction ($HR = 0.55$-0.89), hepatic failure ($HR = 0.28$-0.48), COPD ($HR = 0.45$-0.69), lung

cancer ($HR = 0.47$-0.69), gastrointestinal malignancies ($HR = 0.56$-0.70), and brain malignancies ($HR = 0.63$ for A-P and N-R). All results reached statistical significance ($p < 0.05$, most < 0.001).

0.63 for A-P and N-R). All results reached statistical significance ($p < 0.05$, most < 0.001).

As in the LHS cohort, antiprotozoal exposure was associated with higher risks of specific

adverse outcomes, including hearing loss ($HR = 1.53$-1.65), Sjögren's syndrome/dry eye ($HR = 1.50$-

2.11), retinal detachment ($HR = 1.34$-2.01 for A-P and N-R), and lichen planus ($HR = 1.59$-1.73 for A-P

and N-R).

In summary, these consistent patterns across independent systems warranted mechanistic and

epidemiologic interpretation, addressed in the Discussion.

Discussion

In this study, we leveraged comprehensive electronic health records from large-scale healthcare

networks in two countries to systematically screen for medications associated with increased human

lifespan. Using a medication-wide association approach in a national Israeli cohort, we identified two

antiprotozoal agents, A-P and mefloquine, as strongly and significantly associated with reduced all-

cause mortality and a broad spectrum of age-related morbidities. These findings were independently

validated in the U.S.-based TriNetX network, where consistent reductions in mortality and major age-

related outcomes were observed for these medications, as well as for N-R—a medication widely used

during the COVID-19 pandemic that contains ritonavir, which has known antiprotozoal activity.

Analyses were designed to ensure alignment of time zero between exposed and unexposed groups,

anchoring it to exposure status in the exposed cohort and applying established pharmacoepidemiologic

principles to avoid immortal-time and other time-related biases.[9,10]

The novelty of this work lies in its approach: by systematically comparing medication histories

over a decade in individuals with above- versus below-average longevity within a large population, we

identified a class of medications—antiprotozoals—that consistently exhibit associations with increased

lifespan and a reduced incidence of common life-shortening conditions, including diabetes and its

complications, cardiovascular and cerebrovascular diseases, chronic kidney disease, hepatic failure,

chronic obstructive pulmonary disease, dementia, and various malignancies. Replicating these

associations across two independent healthcare systems in different countries, and for three

mechanistically related but distinct medications, provides convergent evidence for the robustness of

these findings.

These results raise the possibility that many age-related conditions with incompletely understood

etiologies may, at least in part, be driven by unrecognized, chronic protozoal colonization, which may

represent a ubiquitous and overlooked contributor to chronic inflammation, immune dysregulation, and

tissue damage underlying the biology of aging. Reduction of protozoal load through short-course

antiprotozoal therapy may confer long-term health benefits, as observed in both cohorts.

Remarkably, we also observed consistent increases in the incidence of certain adverse outcomes,

including hearing loss, Sjögren's syndrome[11], and lichen planus[12], following antiprotozoal exposure.

Rather than undermining the protective associations, these findings provide key mechanistic insights and

further strengthen the plausibility of our results. These conditions affect cell types and tissues that are

highly sensitive to localized immune-mediated damage, which may arise following the pharmacological

elimination of intracellular pathogens. The abrupt clearance of these pathogens could trigger localized

inflammation and immune activation at sites of prior intracellular colonization, revealing the pathogen

reservoirs while concurrently reducing systemic inflammation.

A key question is which pathogen's elimination could underlie these associations. Based on

global seroprevalence, tissue tropism, and epidemiological links to neurodegenerative and

cardiovascular diseases, we hypothesize that *Toxoplasma gondii* is a likely culprit. As an intracellular

parasite, *T. gondii* can colonize the gut, disseminate hematogenously, establish low-grade infections in

various tissues, including in the CNS, often evading immune detection. Its presence has been associated

with increased risks of dementia[13], schizophrenia[14], and cardiovascular diseases[15], while our findings of

reduced diabetes and its complications following antiprotozoal treatment align with the hypothesis that

eradication of chronic *T. gondii* infection may mitigate systemic inflammation and thromboembolic

risks.

T. gondii is ubiquitous in human environments, with global seroprevalence estimates ranging

from 20% to 80% depending on geography and age. The longer individuals live, the greater their

cumulative likelihood of environmental exposure and eventual parasitic colonization, even in the

absence of overt clinical disease. As an intracellular parasite, *T. gondii* initially colonizes the

gastrointestinal tract, where it may induce chronic low-grade inflammation and promote local immune

evasion. By interfering with host cell apoptosis and modulating immune surveillance, *T. gondii* may

increase the risk of malignancy. Supporting this, we have shown in a recent study that *T. gondii* DNA

signatures are enriched in the stool of individuals with colorectal cancer, indicating active or latent gut

colonization in these patients [16].

Additionally, *T. gondii* has been reported to colonize the skin[17], which is anatomically

contiguous with the gastrointestinal outlet. While evidence is limited, localized colonization of the skin

or mucous membranes occurring more broadly, particularly in aging individuals with declining immune

surveillance may contribute to chronic, non-specific inflammation and insulin resistance, a hallmark of

diabetes mellitus—a condition we found to be reduced following antiprotozoal treatment. Notably, *T.*

gondii infections that remain localized without systemic dissemination may not trigger detectable

serological responses, consistent with the parasite's intracellular lifestyle and immune evasion strategies.

Supporting this hypothesis, several studies have reported increased *T. gondii* seroprevalence among

individuals with diabetes mellitus [18,19].

Furthermore, *T. gondii* is capable of systemic dissemination via hematogenous spread, allowing

it to reach and infect a wide range of cell types, notably neuronal tissue within the central nervous

system (CNS). Increased seropositivity for *T. gondii* has been associated with a range of

neuropsychiatric and neurodegenerative conditions, including dementia and schizophrenia, aligning with

our observation of reduced dementia incidence following antiprotozoal treatment [20–25].

Parasite dissemination into the systemic circulation may precipitate thromboembolic phenomena,

a proposed mechanism for the association of *T. gondii* with cardiovascular and cerebrovascular

morbidity [15,26]. The marked reductions in myocardial infarction and stroke observed following

antiprotozoal treatment in our study are consistent with this hypothesis, suggesting that protozoal

eradication may mitigate thromboembolic risk by reducing systemic parasite burden and associated

vascular inflammation.

Supporting evidence that A-P, mefloquine, and N-R (Paxlovid) possess anti-*Toxoplasma* activity

further strengthens the plausibility of our hypothesis.

Atovaquone is a well-established anti-*Toxoplasma* agent that inhibits the parasite's

mitochondrial electron transport chain, impairing its energy production and replication. It is used in

combination therapies for toxoplasmosis treatment and prophylaxis, with demonstrated efficacy in

suppressing and clearing *T. gondii* infections, including in immunocompromised patients. Proguanil,

while primarily targeting *Plasmodium*, may enhance atovaquone's efficacy by additional mitochondrial

inhibition and by inhibiting dihydrofolate reductase (DHFR), thereby interfering with folate metabolism,

which is also required for *T. gondii* survival and replication.[27,28]

Mefloquine is an antiprotozoal widely used for malaria prophylaxis and treatment, particularly

against *Plasmodium falciparum* strains resistant to chloroquine and other first-line antimalarials.

Importantly, mefloquine has demonstrated both in vitro and in vivo activity against *T. gondii*[29,30].

Animal studies have shown reduced parasite loads and extended survival in infected mice treated with

mefloquine, indicating its ability to target *T. gondii* tissue cysts and tachyzoites through interference

with parasite autophagy and disruption of membrane stability. Additionally, mefloquine is thought to

impair parasite autophagic pathways and mitochondrial function, further contributing to its efficacy

against intracellular protozoa, including *T. gondii*.

Lastly, N-R (Paxlovid) has not been formally studied for *T. gondii* activity; however, ritonavir

and related HIV protease inhibitors have demonstrated *in vitro* anti-*Toxoplasma* activity, likely by

interfering with the parasite's protease systems and replication cycles[31,32]. Furthermore, protease

inhibitors have been investigated for synergistic effects with other anti-*Toxoplasma* agents, supporting

their potential role in suppressing *T. gondii* replication.

Medications used for malarial prophylaxis are typically administered for the duration of travel

(generally several weeks). Combined with their high intracellular penetration, this treatment period may

be sufficient to eliminate or clear a substantial portion of the *T. gondii* burden in the host. By reducing

parasite load below a critical threshold, such treatments could enable the immune system to prevent the

re-expansion of subclinical foci. This mechanism may underlie the durable reductions in chronic

inflammation and the lowered risk of age-related diseases that we observed in both populations,

persisting for up to a decade after exposure.

In contrast, N-R is administered for only five days to prevent COVID-19 complications—a much

shorter course than typical antimalarial regimens—which may limit its effectiveness in eradicating *T.*

gondii. Nevertheless, despite this shorter exposure, we observed similar reductions in all-cause mortality

and age-related morbidities, along with increased risks of the same auditory, visual, and dermatologic

conditions seen with A-P and mefloquine.

The observed associations of antiprotozoal treatment with hearing loss, retinal detachment,

Sjögren's syndrome, and lichen planus further support the biological plausibility of *T. gondii*

involvement. These outcomes align with the parasite's known tissue tropism: congenital toxoplasmosis

is a leading cause of sensorineural hearing loss in infants [33], and seropositivity has been linked to

hearing impairment [34]; toxoplasma retinitis is the most common cause of posterior uveitis worldwide [35];

and cutaneous toxoplasmosis frequently occurs in immunocompromised individuals [17]. Taken together,

these findings suggest that the observed increases in localized conditions after antiprotozoal therapy may

reflect parasite clearance from its canonical reservoirs, triggering tissue-specific pathology while

simultaneously lowering the risk of systemic spread.

Until now, the prevailing view has been that *Toxoplasma gondii* is largely innocuous in

immunocompetent humans, aside from its teratogenic effects in newly infected pregnant women and its

impact on immunocompromised individuals. Consequently, serological testing is rarely performed

outside these contexts. In histopathological examinations, the small, easily overlooked cysts

characteristic of *T. gondii* are typically disregarded or unreported due to the absence of a recognized

clinical correlation. This likely contributes to the underrecognition of its potential long-term harms and

to the absence of therapeutic strategies aimed at parasite clearance in the general population.

Evolutionary considerations relevant to persistent *T. gondii* infection

To place these epidemiologic observations in a broader biological context, we outline below a

testable evolutionary framework that may help explain the observed patterns.

Host death is required for pathogen amplification

Most pathogens gain little by harming their hosts: their success depends on replication and

transmission between living hosts, and excessive virulence is usually selected against[36]. *T. gondii*

belongs to a distinct ecological class. Its sexual reproduction occurs exclusively in the intestines of felids

that consume infected host tissues [37,38], a step essential for genetic recombination and for producing

resistant oocysts in the massive numbers that enable large-scale environmental spread[39]. Predation or

scavenging, both closely coupled to host death, are obligate steps in the parasite's life cycle and therefore

impose strong selection for traits that enable felid consumption of infected tissue [40]. Loss of aversion to

cat odor provides one mechanism by which this process occurs in rodents [41,42]. However, *T. gondii*'s

capacity to spread through a wide variety of host species, including birds, livestock, and humans, is not

explained by rodent-specific behavioral interactions. Instead, any physiological, neurological, or

systemic impairment that increases vulnerability to predation or scavenging can serve the same

reproductive function across host species.

At the same time, felids target prey that provides sufficient biomass, and host impairment

occurring before the host has reached optimal edible size or before completion of a critical reproductive

window may reduce predation success and endanger reservoir stability. Natural selection should

therefore favor parasite traits that increase the host's susceptibility to feline predation while preserving

attainment of adult size and enabling fulfillment of the reproductive phase required for species

continuity.

Moreover, host impairments that emerge after reproduction fall into a period when natural

selection on the host is weak [43,44]. Defenses against late-onset pathology confer little reproductive

advantage and thus would spread poorly. By concentrating pathogenic effects in this post-reproductive

"selection shadow," a parasite may maximize transmission while minimizing host counter-adaptation.

Strategic latency through bradyzoite persistence

After acute infection, *T. gondii* transitions from rapidly replicating tachyzoites to encysted

bradyzoites. These cysts persist for decades in long-lived tissues such as neurons and skeletal muscle

under immune surveillance[45]. Antigen expression is reduced, and the infection is termed "latent," a state

commonly regarded as innocuous and self-limiting in immunocompetent humans.[38]

However, a metabolically restrained form that selectively encysts in long-lived tissues, actively

evades immune elimination, and engages host-specific regulatory and signaling pathways is

evolutionarily costly and incompatible with a transmission cycle that ceases with host death. Such

elaborate persistence and host-adapted regulation would be unlikely to have evolved across such a wide

range of vertebrate hosts unless it contributed to onward transmission. Instead, latency is best

understood as an adaptive strategy that allows the parasite to persist in host tissues until the host has

aged and fulfilled its reproductive role. At that stage, predation becomes advantageous for parasite

transmission, and host debilitation can increase the probability that infected tissues reach a felid without

compromising population continuity.

From an evolutionary perspective, latency is therefore unlikely to represent a benign stalemate,

but rather a finely adapted transmission strategy that defers pathogenic effects to a stage of host life

when such damage can occur without threatening the parasite's reservoir.

Protozoal suppression, mortality and late-life morbidity

In this cohort study, we have identified that exposure to atovaquone–proguanil (A-P) or

mefloquine, two widely used malarial prophylactic agents, was associated with large and sustained

reductions in all-cause mortality over the subsequent decade in Israel, and replicated the findings in the

TriNetX U.S. federated network of approximately 120 million patients, with cohorts rigorously matched

on age, sex, calendar time, and major clinical and demographic variables. Consistency across health

systems and populations makes simple travel- or demography-based confounding unlikely, particularly

in light of the observed balance of major factors of human morbidity.

One parsimonious interpretation of the observed reductions in mortality and morbidity is that

these outcomes share a previously underrecognized common substrate: a silent protozoal infection

whose virulence is delayed and whose burden was reduced by these antiprotozoal treatments. The

observed epidemiologic signals may therefore reflect attenuation of the parasite's contribution to late-life

impairment, a pattern consistent with the evolutionary constraints of *T. gondii*, whose reproductive

success is contingent on late-life host impairments that may enable predation or scavenging by felids.

Schizophrenia

Schizophrenia is an incompletely understood disease, associated with disordered thought

processes and cognitive impairment, for which higher rates of *T. gondii* seropositivity have been

detected across multiple populations [14,20,46,47], along with immune and metabolic abnormalities[48–52]. If

persistent toxoplasmosis contributes to disease risk, two predictions follow: suppression of the parasite

should be protective, and impairment of host mechanisms that normally contain intracellular pathogens

should increase risk. Both patterns were observed in an Israeli cohort study[53].

In a medication-wide screen covering all drugs dispensed in the decade before first schizophrenia

diagnosis, the strongest protective associations clustered around agents with known anti-*Toxoplasma*

activity, including atovaquone–proguanil used for malaria prophylaxis, clindamycin-based regimens

used for acne, and moxifloxacin and oxytetracycline/polymyxin-B ophthalmic drops used to treat eye

infections or for perioperative prophylaxis. Each of these associations was independently replicated in

the TriNetX network with similar effect sizes and directionality. An independent study also reported a

protective association for doxycycline, another tetracycline with anti-*Toxoplasma* effects[54].

Host biological context further supports this interpretation. Before diagnosis, individuals who

later developed schizophrenia showed lower vitamin D and T3 levels, higher rates of liver disease and

alcoholism, reduced mucosal and barrier integrity, and increased prevalence of chronic viral hepatitis,

whereas hepatitis A vaccination and episodes of transient mucosal inflammation were protective.

Together, these features indicate impaired immune containment of intracellular parasites [50], a milieu in

which latent *T. gondii* may shift from quiescence to clinically relevant neurobiological effects.

Dementia, viral triggers, and delayed protozoal virulence

T. gondii seropositivity is consistently higher across the dementia spectrum, from mild cognitive

impairment to Alzheimer's disease[23,24,55]. If latent toxoplasmosis contributes to late-life

neurodegeneration, then interventions that suppress the parasite or prevent its reactivation should reduce

dementia risk, whereas conditions that destabilize immune control should increase it.

This pattern has been observed. In an unsupervised medication-wide screen performed in the

U.K., a significantly lower incidence of Alzheimer's disease was detected among individuals prescribed

atovaquone–proguanil (A-P) or mefloquine, both CNS-penetrant antiprotozoals [56]. The protective

association with A-P was independently detected in Israel and further replicated in large, age-stratified,

rigorously matched U.S. TriNetX cohorts, where protection persisted for more than 10 years after

exposure across multiple age strata [57].

Independent evidence points to a viral contributing effect. Varicella–zoster virus (VZV)

vaccination is associated with reduced dementia risk[58,59], and herpesvirus genomic signatures are

enriched in Alzheimer's disease brain tissue, while antiviral therapy is associated with lower dementia

incidence [60,61]. Experimental and clinical studies show that herpesvirus infection can impair immune

control of latent *T. gondii* and induce protozoal reactivation within the central nervous system[62].

Consistent with this interaction model, the protective association of A-P was observed mostly for

individuals who had not received VZV vaccination, and the protective association of VZV vaccination

was observed mostly among those not exposed to A-P, suggesting that both act on the same downstream

pathogenic pathway (Figure 2). Longitudinal serologic data further support this framework: individuals

seropositive for *T. gondii* had higher subsequent risk of dementia, with serology preceding diagnosis by

many years.

Together, medication, vaccination, and serologic evidence converge on a coherent model in

which latent protozoal persistence, whose reactivation is enabled by viral coinfection, is associated with

heterogeneous late-life neurodegeneration.

Cancer

Increased *T. gondii* seropositivity has been observed in both colorectal cancer and glioma in

large prospective cohorts, with timing indicating that infection occurs before tumor development[63–65]. If

latent toxoplasmosis contributes to carcinogenesis, then protozoal suppression should reduce cancer risk,

and this pattern is observed.

In Sweden, use of atovaquone–proguanil (A-P) was associated with reduced colorectal cancer

incidence [66]. This protective association was independently replicated in the TriNetX network, where

reduced risk of gastrointestinal malignancies persisted for up to 10 years after exposure and extended to

pancreatic cancer[16]. The durability of protection following brief prophylaxis is more consistent with

suppression of a persistent carcinogenic factor than with a direct tissue effect occurring only during drug

exposure.

Microbiome sequencing experiments provide complementary clues. Reanalysis of a large

colorectal cancer metagenomic dataset (PRJEB6070) using protozoa-inclusive reference libraries

identified *T. gondii* as the single most discriminatory taxon, exceeding *Fusobacterium*, which was the

most discriminatory taxon in the original study [16]. *T. gondii* DNA was detected in 22.1% of cancer

samples compared with 1.53% of controls, with abundance increasing progressively from normal

mucosa to adenoma to carcinoma (Figure 3).

Together, prospective serology, durable pharmacoepidemiologic protection, and direct detection

of parasite DNA along the adenoma-carcinoma sequence converge on a coherent model in which

persistent toxoplasmosis is implicated in malignant transformation in the human gut and possibly

beyond.

Synthesis and conclusion: a parasite optimized for delayed morbidity

Across independent disease domains, convergent evidence summarized eveals a coherent and

internally consistent pattern that suggests *T. gondii* involvement in a wide range of pathogenetic

processes.

No currently established host-centered degenerative model readily explains this cross-domain

convergence. In contrast, parasite-mediated health deterioration that emerges in late life follows

naturally from the evolutionary constraints dictated by *T. gondii*'s life cycle. Because the parasite can

complete sexual reproduction only when infected host tissue is consumed by a felid, parasite fitness is

inseparable from host death. This ecological constraint would therefore select parasite traits optimized to

produce health or behavioral impairment in late adult life, when predation or scavenging becomes

advantageous for parasite transmission without endangering population continuity.

In humans, who are frequently and repeatedly exposed to *T. gondii* through environmental

oocysts in soil, water, and fresh produce, as well as through consumption of infected meat, seafood, and

unpasteurized milk, such parasite-mediated impairment would be expected to manifest as disorders that

cluster in later life, including vascular, neurodegenerative, and malignant disease. Long-term tissue

persistence, delayed virulence, and the fact that serologic responses may decline or fail to capture low-

grade, tissue-restricted infection make it possible that a major contributor to human morbidity could

have remained largely unrecognized.

Together, evolutionary logic and human data are consistent with a testable hypothesis: a

measurable fraction of late-life morbidity may reflect delayed consequences of *T. gondii* infection rather

than purely intrinsic processes. If correct, at least some age-related diseases may depend on targetable

infectious factors[67], with substantial health implications .Based on the epidemiologic observations of this

study, we hypothesize that chronic *T. gondii* colonization may contribute to aging-related conditions,

thereby explaining the association of antiprotozoal therapies with reduced mortality and morbidity. Our

findings raise the possibility that even short courses of antiprotozoal treatment may confer long-term

benefits by lowering the burden of T. gondii. These results underscore the need for further research to

determine the prevalence of *T. gondii* infection in aging-related diseases and to assess whether targeted

clearance strategies—ideally designed to minimize collateral tissue damage—could help mitigate age-

associated morbidity and mortality.

 Limitations

Despite the strengths of our large-scale, systematically matched analyses and replication across

independent populations, this study has several limitations. First, as an observational study, residual

confounding cannot be rigorously excluded. However, the consistent observation of both protective and

adverse associations (e.g., hearing loss, Sjögren's disease, lichen planus) across large cohorts from

different countries, for two distinct antimalarials, and in TriNetX also for N-R—a medication

administered during COVID-19 primarily to older and less healthy patients and provided at no cost

across socioeconomic groups—argues strongly against selection or indication bias as the main

explanation.

Second, in the LHS exploratory analysis (Analysis A), individuals exposed to antimalarials did

exhibit slightly healthier baseline characteristics, which may explain part, though not all, of the observed

risk reduction. In this design, survival status was used to define cases and controls, reflecting its role as

an exploratory, hypothesis-generating screen rather than a causal inference framework. While it could in

principle amplify baseline differences between groups, these concerns were addressed in Analyses B and

C, where group assignment was based directly on first medication exposure (defining the index date)

and outcomes were analyzed longitudinally using survival models. In particular, Analysis C further

minimized bias through propensity-score matching, which ensured rigorous baseline balance across

demographic and clinical factors, including race/ethnicity, BMI, diabetes status, HbA1c, and smoking

status.

Finally, while the magnitude of the protective associations is striking, their replication across two

independent healthcare systems supports the interpretation that these signals are unlikely to be artifacts

of a single study design. The persistence of associations with age-related diseases of distinct etiology

and disease course, and across outcomes that often occur in otherwise healthy individuals (such as

malignancy and myocardial infarction), further reduces the likelihood of confounding as the primary

explanation. Moreover, having constructed the cohorts appropriately and empirically validated the

absence of bias through baseline comparisons, observing concordant protective effects together with

specific adverse associations (hearing loss, Sjögren's disease, lichen planus) across drugs with unrelated

primary indications provides additional reassurance that the findings are genuine and not primarily

attributable to indication bias.

Conclusion

Overall, the observed protective effects of antiprotozoal medications against mortality and a

broad range of aging-associated diseases—together with consistent increases in conditions linked to

canonical reservoirs of *Toxoplasma gondii*, observed across two countries and three drugs with distinct

indications—generate the hypothesis that chronic protozoal colonization, possibly by *T. gondii*, may be

an underrecognized contributor to age-related morbidity. The spectrum of affected outcomes, spanning

metabolic, cardiovascular, cerebrovascular, neurodegenerative, and malignant diseases, highlights the

potential public health significance of this finding. These results raise the possibility that targeted

eradication or suppression of protozoal infections could represent a novel strategy to reduce age-related

disease burden and lower mortality. This hypothesis can be evaluated in future studies, including

serologic or microbiome-based approaches. Prospective interventional studies may help confirm

causality and evaluate therapeutic potential.

Methods

Study design

This research was performed in three sequential stages, as illustrated in Figure 1. Each stage was designed to build upon the previous one:

- **Analysis A (Screening stage):** A systematic, medication-wide case-control analysis in a national Israeli cohort to identify candidate medications associated with longevity.

- **Analysis B (Validation-Exploration stage):** A matched cohort study within LHS focused on the candidate antiprotozoal medications identified in Analysis A, aimed at validating associations with mortality and exploring morbidity outcomes.

- **Analysis C (Replication stage):** Independent validation in the U.S.-based TriNetX research network using a matched cohort design, including both the candidate antiprotozoals and nirmatrelvir-ritonavir (N-R), selected as an additional comparator with predicted antiprotozoal properties.

Design and reporting adhere to STROBE and RECORD-PE guidelines for pharmacoepidemiologic cohort studies. At each stage, established pharmacoepidemiologic principles were applied to minimize potential sources of bias, including alignment of time zero and prevention of immortal-time and other time-related biases.[9,10]

Analysis A: LHS Cohort to Identify Drugs Associated with Increased Longevity

The first stage (Analysis A) was a matched case-control screen designed to identify medications associated with longevity in Leumit Health Services (LHS), one of four nationwide health providers in Israel, delivering comprehensive healthcare to approximately 730,000 members. All Israeli citizens are entitled to comprehensive health insurance and receive a standardized package of healthcare services and medications, as defined by the national "Health Basket" committee. LHS operates a centralized

electronic health record (EHR) system, maintaining over two decades of meticulously curated data,

including patient demographics, medical diagnoses, healthcare encounters, laboratory test results, and

records of prescribed medications. In addition, LHS maintains a comprehensive network of affiliated

pharmacies, enabling reliable tracking of medication purchases by its members—including over-the-

counter medications—which allows for the identification of associations between medication uptake and

clinical outcomes.

Cohort eligibility included current and former LHS members with electronic records of medical

visits occurring after age 60. Electronic health records have been available at LHS since 2002;

Individuals were eligible only if they had at least 10 years of observable electronic history since their

first EHR record. This requirement ensured both cases and controls had comparable longitudinal data

availability before cohort entry. Data were extracted from the LHS central data warehouse,

encompassing diagnoses and medication purchases through December 31, 2024. Structured query

language (SQL) and Python scripts were used to automate data retrieval. Socioeconomic status (SES)

was determined based on geocoded residential addresses and classified on a 1-20 scale using the Points

Location Intelligence® database, which correlates strongly with official national SES indicators.

Using sex-specific longevity thresholds derived from median life expectancy in our health

system—84 years for females and 77 years for males—we constructed two groups of eligible

individuals: a high-longevity group, comprising individuals who exceeded the cutoff and were alive at

the time of data extraction, and a below-average longevity group, comprising individuals who died

before reaching the respective cutoff age. For each individual who died before the threshold, we

matched a control with above-average longevity based on sex, birth year, socioeconomic status (SES)

group, year of first EHR record in LHS, and year of first ambulatory visit occurring at least 10 years

after his first EHR record. Matching prioritized individuals with the closest birth dates and was

performed without replacement, such that each control could be matched to only one case. The index

date was defined as the ambulatory visit occurring ten years after the first available EHR record for each

individual, ensuring comparable duration of electronic medical history prior to index.

Analysis A: Systemic Screen Procedure

We compared, for each medication, the proportion of individuals with at least one recorded

purchase in the 10 years preceding the index date. Medications were identified according to their

Anatomical Therapeutic Chemical (ATC) classification, and qualifying purchases were restricted to this

fixed 10-year look-back window. For each ATC class, purchase proportions were compared between the

above-average and below-average longevity groups using Fisher's exact test, with false discovery rate

(FDR) correction for multiple testing. Signals were defined according to pre-specified criteria

prioritizing large effect sizes (odds ratio < 0.5) together with strong statistical support (FDR<0.5%),

consistent with a hypothesis-generating screening objective.

Analysis B: Validation-Exploration Cohort of LHS Patients Exposed to Antiprotozoals

To validate the observed association with reduced mortality and to explore which disease

reductions might underlie this effect, we constructed a cohort of individuals aged 40 to 85 who had

received at least one prescription for atovaquone-proguanil (A-P) or mefloquine. Each exposed

individual was matched to 20 control patients of the same sex, age, socioeconomic status (SES) group,

and year of first EHR record, with priority given to controls with the closest birth dates. The index date

was defined as the first recorded purchase of the respective medication for the case group, and this exact

calendar date was assigned to each matched control. Controls were selected only from individuals

confirmed to be alive and active members of LHS at that date, ensuring identical time zero for both

groups and preventing immortal time or calendar bias. Matching was performed without replacement, so

that each control could be used only once. Because atovaquone-proguanil and mefloquine exposures

were rare (≈1% of age-eligible individuals), undocumented use prior to first EHR record would be

uncommon and unlikely to materially influence exposure classification.

We compared all-cause mortality and the incidence of age-related conditions using a predefined

curated list of 200 ICD-coded medical outcomes routinely monitored at Leumit Research Institute.

Time-to-event analyses were conducted using Cox proportional hazards models to estimate hazard ratios

(HRs) with 95% confidence intervals. Proportional hazards assumptions were assessed using Schoenfeld

residuals. Additional adjustment (age, smoking status, number of ambulatory visits, pregnancy history)

was applied in the Cox models, based on the patient status at their assigned index dates. Follow-up was

censored at the date of death or the last recorded medical encounter for individuals who remained alive.

For each outcome, individuals with a documented diagnosis prior to the index date were excluded from

the corresponding analysis.

Analysis C: TriNetX Validation Cohort

To validate the mortality reduction observed in LHS and to test whether associations could be

reproduced in an independent U.S. population, we conducted analyses using TriNetX, a federated

research network comprising electronic health record (EHR) data from 70 healthcare organizations and

covering more than 120 million patients. Queries were executed online in July 2025.

Validation cohorts included individuals aged 70–89 years at the time of cohort extraction who

had either a documented prescription or a qualifying ambulatory visit, which served as the index event.

In TriNetX, current age is computed automatically as the time elapsed between the individual's date of

birth and cohort extraction date, irrespective of whether the individual is alive or deceased. For

decedents, age is not derived from the date of death; the system abstracts the date of birth and applies the

same extraction timestamp used for the cohort query. Accordingly, current age does not condition on

survival status and cannot introduce immortal-time bias.

Eligibility additionally required documentation of BMI within the year preceding the index

event, ensuring that metabolic matching was based on measurements with comparable recency in all

participants. Cases were defined as individuals with a recorded prescription for the medication of

interest (atovaquone–proguanil, mefloquine, or nirmatrelvir–ritonavir); controls were individuals with a

qualifying ambulatory visit, both within the same BMI-referenced window.

In TriNetX, the index date is automatically defined as the first point at which all inclusion

criteria are simultaneously satisfied. For exposed individuals, this necessarily corresponds to their first

recorded prescription, and follow-up contributes only after this event; no person-time prior to exposure

contributes to the exposed cohort. We used the TriNetX Compare Outcomes pipeline, in which exposed

individuals are matched 1:1 to controls using greedy nearest-neighbor propensity-score matching

without replacement, ensuring that each control is used only once. Controls were not required to remain

unexposed during follow-up, thereby avoiding bias from conditioning on future exposure. TriNetX

simply prevents individuals in the exposed cohort from being simultaneously selected as controls,

without restricting subsequent medication use. Propensity score matching (PSM) was applied to balance

groups on age, sex, ethnicity, race, smoking status, diabetes diagnosis, BMI, and HbA1c levels at

baseline. For nirmatrelvir-ritonavir, availability beginning in 2021 resulted in a modest calendar-time

shift, which is intrinsic to its recent introduction. Outcomes were compared using Kaplan-Meier survival

curves and Cox proportional hazards models to estimate hazard ratios (HRs) with 95% confidence

intervals.

Guided by the observed associations in LHS, we evaluated the following outcomes:

• **All-cause mortality**

• **Diabetes** (ICD-10: E08-E13; or incident HbA1c ≥6.5%)

• **Dementia** (F03, G30)

•   **Renal insufficiency** (eGFR <45 mL/min/1.73 m²), chosen to ensure a uniform and clinically

meaningful definition across healthcare organizations

•   **Hepatic failure** (K72)

•   **Congestive heart failure (CHF)** (I50)

•   **Myocardial infarction (MI)** (I21)

•   **Malignancies**: gastrointestinal (C15-C26), urinary tract (C64-C68), brain (C71), lung (C30-C39)

•   **Chronic Obstructive Pulmonary Disease (COPD)** (J43-J44)

•   **Hearing loss** (H90-H91)

•   **Sjögren's syndrome** (M35.0)

•   **Retinal detachment** (H33)

•   **Lichen planus** (L43)

These codes were intentionally restricted to ensure uniform diagnostic specificity across

healthcare systems, acknowledging reduced sensitivity but minimizing differential misclassification

bias. Follow-up was censored at the date of the last recorded medical encounter, up to 4000 days (~11

years) after the index date. For each outcome, individuals with a documented diagnosis prior to the

index date were excluded from the corresponding analysis.

Data processing in LHS

Data from LHS were extracted from the centralized EHR system and processed using T-SQL queries and Python 3.11 scripts developed by the Leumit Research Institute. To ensure anonymity, all patient identifiers were removed and replaced with study-specific codes prior to analysis. Medication exposure was determined from pharmacy purchase records, covering both prescription and over-the-counter drugs, up to 10 years prior to the index date. Medications were classified according to the Anatomical Therapeutic Chemical (ATC) system.

Statistical analyses

For LHS data, Fisher's exact test was used to compare categorical variables, and two-tailed t-tests were applied for continuous variables. Survival between treatment groups was compared using the log-rank test. All tests were two-tailed, with P-values below 0.05 considered statistically significant. Analyses of LHS data were conducted in R version 4.4.

For TriNetX data, analyses were performed within the TriNetX platform using the built-in "compare outcome" analysis pipeline, which applies Kaplan-Meier estimators and Cox proportional hazards models to propensity score matched cohorts.

Data Availability Statement

The LHS patient-level data generated and analyzed in this study are not publicly available due to patient privacy regulations. Access may be granted to qualified researchers pending approval by the Leumit Health Services Institutional Review Board. Aggregated data supporting the findings of this study are available from the corresponding author upon reasonable request.

TriNetX data are accessible only to licensed member organizations of the TriNetX network, in compliance with HIPAA and institutional guidelines.

Ethics Statement

The study was reviewed and approved by the Leumit Health Services Institutional Review Board (IRB). Ethical approval was granted, with a waiver of informed consent (LEU-0020-24). All LHS data were analyzed retrospectively and in a fully de-identified manner.

TriNetX data are de-identified and analyzed under agreements with participating health organizations, compliant with HIPAA and institutional guidelines.

Acknowledgements

Funding

This study was funded internally by Leumit Health Services. ER was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Conflict of Interest

The authors have declared that there are no conflicts of interest in relation to the subject of this study.

Use of Artificial Intelligence Tools

During manuscript preparation, the authors used ChatGPT (GPT-4o, OpenAI) for language refinement and style editing. The content, data interpretation, and conclusions are entirely the responsibility of the authors, and the AI tool did not contribute to the scientific analyses or results.

References

1. Israel, A. *et al.* Type 2 Diabetes in Patients with G6PD Deficiency. *New England Journal of Medicine* **391**, 568–569 (2024).

2. Israel, A. *et al.* Identification of drugs associated with reduced severity of covid-19 – a case-control study in a large population. *Elife* **10**, (2021).

3. Israel, A. *et al.* Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. *The BMJ* **375**, e067873 (2021).

4. Wang, T. *et al.* Divergent age-associated and metabolism-associated gut microbiome signatures modulate cardiovascular disease risk. *Nat. Med.* **30**, 1722–1731 (2024).

5. Afzaal, M. *et al.* Human gut microbiota in health and disease: Unveiling the relationship. *Front. Microbiol.* **13**, (2022).

6. Sun, J. *et al.* Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation. *NPJ Biofilms Microbiomes* **11**, 43 (2025).

7. Toh, T. S. *et al.* Gut microbiome in Parkinson's disease: New insights from meta-analysis. *Parkinsonism Relat. Disord.* **94**, 1–9 (2022).

8. Zhou, K., Baranova, A., Cao, H., Sun, J. & Zhang, F. Gut microbiome and schizophrenia: insights from two-sample Mendelian randomization. *Schizophrenia* **10**, 75 (2024).

9. Suissa, S. & Dell'Aniello, S. Time□related biases in pharmacoepidemiology. *Pharmacoepidemiol. Drug Saf.* **29**, 1101–1110 (2020).

10. Suissa, S. Immortal Time Bias in Pharmacoepidemiology. *Am. J. Epidemiol.* **167**, 492–499 (2008).

11. Negrini, S. *et al.* Sjögren's syndrome: a systemic autoimmune disease. *Clin. Exp. Med.* **22**, 9–25 (2022).

661   12.   Le Cleach, L. & Chosidow, O. Lichen Planus. *New England Journal of Medicine* **366**, 723–732
662   (2012).

663   13.   Yang, H.-Y. *et al.* Risk of dementia in patients with toxoplasmosis: a nationwide, population-
664   based cohort study in Taiwan. *Parasit. Vectors* **14**, 435 (2021).

665   14.   Sutterland, A. L. *et al.* Beyond the association. Toxoplasma gondii in schizophrenia, bipolar
666   disorder, and addiction: systematic review and meta☐analysis. *Acta Psychiatr. Scand.* **132**, 161–
667   179 (2015).

668   15.   Egorov, A. I. *et al.* Latent Toxoplasma gondii infections are associated with elevated biomarkers
669   of inflammation and vascular injury. *BMC Infect. Dis.* **21**, 188 (2021).

670   16.   Israel, A. *et al.* Atovaquone-proguanil and reduced digestive cancer risk: a *Toxoplasma gondii*
671   connection. *Gut Microbes* **17**, (2025).

672   17.   Leyva, W. H. & Santa Cruz, D. J. Cutaneous toxoplasmosis. *J. Am. Acad. Dermatol.* **14**, 600–605
673   (1986).

674   18.   Soltani, S. *et al.* The Probable Association between Chronic Toxoplasma gondii Infection and
675   Type 1 and Type 2 Diabetes Mellitus: A Case-Control Study. *Interdiscip. Perspect. Infect. Dis.*
676   **2021**, 1–6 (2021).

677   19.   Catchpole, A. *et al.* Association between Toxoplasma gondii Infection and Type-1 Diabetes
678   Mellitus: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* **20**, 4436
679   (2023).

680   20.   Flegr, J. Effects of Toxoplasma on Human Behavior. *Schizophr. Bull.* **33**, 757–760 (2007).

681   21.   Nayeri, T., Sarvi, S., Sharif, M. & Daryani, A. Toxoplasma gondii: A possible etiologic agent for
682   Alzheimer's disease. *Heliyon* **7**, e07151 (2021).

22.   Torrey, E. F., Bartko, J. J. & Yolken, R. H. Toxoplasma gondii and Other Risk Factors for

Schizophrenia: An Update. *Schizophr. Bull.* **38**, 642–647 (2012).

23.   Wang, J. *et al.* Analysis of the Correlation Between Toxoplasma gondii Seropositivity and

Alzheimer's Disease. *Pathogens* **13**, 1021 (2024).

24.   Wiener, R. C., Waters, C. & Bhandari, R. The association of Toxoplasma gondii IgG and

cognitive function scores: NHANES 2013–2014. *Parasitol. Int.* **78**, 102123 (2020).

25.   Israel, A. *et al.* Atovaquone/Proguanil Use and Zoster Vaccination Are Associated with Reduced

Alzheimer's Disease Risk in Two Cohorts: Implications for a Latent *Toxoplasma gondii*

Mechanism. Preprint at https://doi.org/10.1101/2025.03.07.25323566 (2025).

26.   Alhusseiny, S. M., Saleh, N. E., El-Zayady, W. M., Hussein, M. S. & El-Beshbishi, S. N.

Association between *Toxoplasma gondii* infection and coronary atherosclerosis. *Trans. R. Soc.*

Trop. Med. Hyg. **115**, 1190–1197 (2021).

27.   Spencer, C. M. & Goa, K. L. Atovaquone. *Drugs* **50**, 176–196 (1995).

28.   KOVACS, J. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. *The*

Lancet **340**, 637–638 (1992).

29.   Secrieru, A., Costa, I. C. C., O'Neill, P. M. & Cristiano, M. L. S. Antimalarial Agents as

Therapeutic Tools Against Toxoplasmosis—A Short Bridge between Two Distant Illnesses.

Molecules **25**, 1574 (2020).

30.   El Sharazly, B. M. *et al.* Mefloquine loaded niosomes as a promising approach for the treatment

of acute and chronic toxoplasmosis. *Acta Trop.* **239**, 106810 (2023).

31.   Alfonso, Y. & Monzote, L. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan

Parasites. *Open Med. Chem. J.* **5**, 40–50 (2011).

32.   Derouin, F. & Santillana-Hayat, M. Anti- *Toxoplasma* Activities of Antiretroviral Drugs and

Interactions with Pyrimethamine and Sulfadiazine In Vitro. *Antimicrob. Agents Chemother.* **44**,

2575–2577 (2000).

33.   Boyer, K. M. *et al.* Risk factors for Toxoplasma gondii infection in mothers of infants with

congenital toxoplasmosis: Implications for prenatal management and screening. *Am. J. Obstet.*

Gynecol. **192**, 564–571 (2005).

34.   Getzmann, S. *et al.* Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the

Adult Life Span. *Life (Basel).* **14**, (2024).

35.   Holland, G. N. Ocular toxoplasmosis: a global reassessment. *Am. J. Ophthalmol.* **136**, 973–988

(2003).

36.   Shukla, R., Soni, J., Kumar, A. & Pandey, R. Uncovering the diversity of pathogenic invaders:

insights into protozoa, fungi, and worm infections. *Front. Microbiol.* **15**, (2024).

37.   DUBEY, J. & JONES, J. Toxoplasma gondii infection in humans and animals in the United

States. *Int. J. Parasitol.* **38**, 1257–1278 (2008).

38.   Montoya, J. & Liesenfeld, O. Toxoplasmosis. *The Lancet* **363**, 1965–1976 (2004).

39.   Martorelli Di Genova, B., Wilson, S. K., Dubey, J. P. & Knoll, L. J. Intestinal delta-6-desaturase

activity determines host range for Toxoplasma sexual reproduction. *PLoS Biol.* **17**, e3000364

(2019).

40.   Innes, E. A. Toxoplasmosis: Comparative species susceptibility and host immune response.

Comp. Immunol. Microbiol. Infect. Dis. **20**, 131–138 (1997).

41.   Webster, J. P. The Effect of Toxoplasma gondii on Animal Behavior: Playing Cat and Mouse.

Schizophr. Bull. **33**, 752–756 (2007).

42.   Tong, W. H., Pavey, C., O'Handley, R. & Vyas, A. Behavioral biology of Toxoplasma gondii

infection. *Parasit. Vectors* **14**, 77 (2021).

43.   Medawar, P. B. *An Unsolved Problem of Biology*. (H.K. Lewis, London, 1952).

44.   Williams, G. C. Pleiotropy, natural selection, and the evolution of senescence. *Evolution (N Y).*

11, 398–411 (1957).

45.   Sullivan, W. J. & Jeffers, V. Mechanisms of *Toxoplasma gondii* persistence and latency. *FEMS*

Microbiol. Rev. **36**, 717–733 (2012).

46.   Cetinkaya, Z., Yazar, S., Gecici, O. & Namli, M. N. Anti-Toxoplasma gondii Antibodies in

Patients With Schizophrenia--Preliminary Findings in a Turkish Sample. *Schizophr. Bull.* **33**,

789–791 (2007).

47.   Torrey, E. F., Bartko, J. J. & Yolken, R. H. Toxoplasma gondii and Other Risk Factors for

Schizophrenia: An Update. *Schizophr. Bull.* **38**, 642–647 (2012).

48.   Cui, X., McGrath, J. J., Burne, T. H. J. & Eyles, D. W. Vitamin D and schizophrenia: 20 years on.

Mol. Psychiatry **26**, 2708–2720 (2021).

49.   Brand, B. A., de Boer, J. N. & Sommer, I. E. C. Estrogens in schizophrenia: progress, current

challenges and opportunities. *Curr. Opin. Psychiatry* **34**, 228–237 (2021).

50.   Khandaker, G. M. *et al.* Inflammation and immunity in schizophrenia: implications for

pathophysiology and treatment. *Lancet Psychiatry* **2**, 258–270 (2015).

51.   Müller, N., Weidinger, E., Leitner, B. & Schwarz, M. J. The role of inflammation in

schizophrenia. *Front. Neurosci.* **9**, (2015).

52.   Misiak, B. *et al.* Thyroid hormones in persons with schizophrenia: A systematic review and meta-

analysis. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **111**, 110402 (2021).

53.   Israel, A. *et al.* Systematic screening identifies medication and disease factors associated with

schizophrenia risk. *Brain Behav. Immun.* **131**, 106135 (2026).

54.   Lång, U. *et al.* Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia:

An Emulated Target Trial. *American Journal of Psychiatry*

https://doi.org/10.1176/appi.ajp.20240958 (2025) doi:10.1176/appi.ajp.20240958.

55.   Kusbeci, O. Y., Miman, O., Yaman, M., Aktepe, O. C. & Yazar, S. Could Toxoplasma gondii

Have any Role in Alzheimer Disease? *Alzheimer Dis. Assoc. Disord.* **25**, 1–3 (2011).

56.   Wilkinson, T. *et al.* Drug prescriptions and dementia incidence: a medication-wide association

study of 17000 dementia cases among half a million participants. *J. Epidemiol. Community*

Health (1978). **76**, 223–229 (2022).

57.   Israel, A. *et al.* Atovaquone/Proguanil Use and Zoster Vaccination Are Associated with Reduced

Alzheimer's Disease Risk in Two Cohorts: Implications for a Latent *Toxoplasma gondii*

Mechanism. *under review, preprint available in MedRxiv* Preprint at

https://doi.org/10.1101/2025.03.07.25323566 (2025).

58.   Taquet, M., Dercon, Q., Todd, J. A. & Harrison, P. J. The recombinant shingles vaccine is

associated with lower risk of dementia. *Nat. Med.* **30**, 2777–2781 (2024).

59.   Pomirchy, M. *et al.* Herpes Zoster Vaccination and Dementia Occurrence. *JAMA*

https://doi.org/10.1001/JAMA.2025.5013 (2025) doi:10.1001/JAMA.2025.5013.

60.   Readhead, B. *et al.* Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of

Molecular, Genetic, and Clinical Networks by Human Herpesvirus. *Neuron* **99**, 64-82.e7 (2018).

61.   Tzeng, N.-S. *et al.* Anti-herpetic Medications and Reduced Risk of Dementia in Patients with

Herpes Simplex Virus Infections—a Nationwide, Population-Based Cohort Study in Taiwan.

Neurotherapeutics **15**, 417–429 (2018).

62.　Chapuis, A., Chabrot, C., Mirand, A., Poirier, P. & Nourrisson, C. Encephalitis caused by an

unusual human herpes virus type 6 and Toxoplasma gondii co-infection in a cord blood transplant

recipient. *International Journal of Infectious Diseases* **46**, 79–81 (2016).

63.　Yu, Y. *et al.* Increased Risk of *Toxoplasma gondii* Infection in Patients with Colorectal Cancer in

Eastern China: Seroprevalence, Risk Factors, and a Case–Control Study. *Biomed Res. Int.* **2020**,

(2020).

64.　Abdollahi, A. *et al.* Toxoplasma gondii infection/exposure and the risk of brain tumors: A

systematic review and meta-analysis. *Cancer Epidemiol.* **77**, 102119 (2022).

65.　Hodge, J. M. *et al.* <scp> *Toxoplasma gondii* </scp> infection and the risk of adult glioma in two

prospective studies. *Int. J. Cancer* **148**, 2449–2456 (2021).

66.　Zhang, N., Sundquist, J., Sundquist, K. & Ji, J. Proguanil and atovaquone use is associated with

lower colorectal cancer risk: a nationwide cohort study. *BMC Med.* **20**, 439 (2022).

67.　Kennedy, B. K. *et al.* Geroscience: Linking Aging to Chronic Disease. *Cell* **159**, 709–713 (2014).

785
786
787

788   **Author contributions:**

789   Conceptualization: AI, EMe, EMa

790   Methodology: AI, EMe

791   Investigation: AI, SI, EMe

792   Writing - original draft: AI

793   Writing - review & editing: AI, AW, SI, SA, SV, EMa, Eme, ER

794   **Materials & Correspondence:** Correspondence and requests for materials should be addressed to AI
795

796   **Funding:** This research was internally funded by Leumit Health Services (LHS) and was supported in
797   part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center
798   for Cancer Research. The content of this publication does not necessarily reflect the views or policies of
799   the Department of Health and Human Services, nor does mention of trade names, commercial products,
800   or organizations imply endorsement by the U.S. Government.
801
802   **Conflict of Interest Statement:** The Authors declare that there are no conflicts of interest in relation to

803   the subject of this study.

Abbreviations

A-P: atovaquone-proguanil

BMI: Body Mass Index

BP: Blood pressure

CHF: Congestive Heart Failure

CI: Confidence Interval

CNS: Central nervous system

COPD: Chronic Obstructive Pulmonary Disorder

EHR: Electronic health records

FDR: False Discovery Rate

GI: Gastrointestinal

GFR: Glomerular Filtration Rate

HbA1c: Hemoglobin A1c

HCO: Healthcare organizations

HR: Hazard Ratio

ICD: International Classification of Diseases

LHS: Leumit Health Services

MI: Myocardial Infarction

N-R: nirmatrelvir-ritonavir

OR: Odds Ratio

PSM: Propensity score matching

SES: Socioeconomic status

SMD: Standardized Mean Difference

Table 1. Demographic and clinical characteristics of the LHS exploratory longevity cohort (Analysis A).

A. at the index date

		Case N=14,986	Control N=14,986	P-value	Odds Ratio	SMD
Sex	Female	7,617 (50.8 %)	7,617 (50.8 %)	1.000	1	
	Male	7,369 (49.2 %)	7,369 (49.2 %)	1.000	1	
Age (years)		70.9 ± 5.9	71.0 ± 5.9	0.098		-0.019
Age category	**60-69**	6,311 (42.11 %)	6,244 (41.67 %)	0.433	1.02 [0.97 to 1.07]	
	70-79	7,303 (48.73 %)	7,317 (48.83 %)	0.881	1.00 [0.95 to 1.04]	
	80-89	1,372 (9.16 %)	1,425 (9.51 %)	0.293	0.96 [0.89 to 1.04]	
Year of index date	mean ± SD	2012 ± 2	2012 ± 2	1.000		0.000
	median [IQR]	2013 [2012 ; 2013]	2013 [2012 ; 2013]			0.000
Year of first EHR record	mean ± SD	2002 ± 2	2002 ± 2	1.000		0.000
	median [IQR]	2003 [2002 ; 2003]	2003 [2002 ; 2003]			0.000
Weight (kg)		77.5 ± 17.7	76.3 ± 14.6	<0.001		0.076
Height (cm)		165 ± 10	164 ± 10	0.030		0.030
Body Mass Index (kg/m^2)		29.1 ± 6.0	28.5 ± 4.8	<0.001		0.127
BP systolic (mmHg)		134 ± 20	133 ± 17	0.104		0.019
BP diastolic (mmHg)		76.8 ± 10.1	77.5 ± 9.0	<0.001		-0.079
Smoking status	Non-smoker	6,705 (73.6 %)	12,067 (84.3 %)	<0.001	0.52 [0.49 to 0.55]	
	Past smoker	485 (5.32 %)	562 (3.93 %)	<0.001	1.38 [1.21 to 1.56]	
	Smoker	1,919 (21.1 %)	1,684 (11.8 %)	<0.001	2.00 [1.86 to 2.15]	
Socio-economic status (1-20)		9.50 ± 3.14	9.55 ± 3.17	0.266		

B. at the end of follow-up

		Case N=14,986	Control N=14,986	P-value	Odds Ratio	SMD
Age (years) #		74.3 ± 5.7	83.6 ± 6.5	<0.001		-1.213
Age category #	**50-59**	7 (0.047 %)		0.016	Inf [1.44 to Inf]	
	60-69	3,051 (20.4 %)		<0.001	Inf [1050.26 to Inf]	
	70-79	8,529 (56.9 %)	4,639 (31.0 %)	<0.001	2.95 [2.81 to 3.09]	
	80-89	3,399 (22.7 %)	7,516 (50.2 %)	<0.001	0.29 [0.28 to 0.31]	
	90-		2,831 (18.9 %)	<0.001	0.00 [0.00 to 0.00]	
died during period		14,986 (100 %)		<0.001	Inf [8402.05 to Inf]	

Panel A shows baseline demographic and clinical characteristics at the index date, comparing
individuals who died before reaching the sex-specific median life expectancy (cases) with matched
individuals who survived beyond it (controls). Panel B shows the same characteristics at the end of
follow-up.
Continuous variables are presented as mean ± standard deviation (SD), with p-values from two-tailed t-
tests. Categorical variables are shown as counts and percentages, with p-values from Fisher's exact tests.
Odds ratios (OR) with 95% confidence intervals (CI) represent associations with case status.
Standardized mean differences (SMD; Cohen's d) are provided as measures of effect size.
IQR: Interquartile range
845
846   # Here, age reflects the maximal age reached at the end of follow-up, taken at the date of death for
847   deceased individuals.
848

Table 2. Demographic and clinical characteristics of the LHS cohort of individuals treated with
atovaquone-proguanil or mefloquine versus matched controls (Analysis B).

		Case N=3,876	Control N=77,820	P-value	Odds Ratio	SMD
Sex	Female	2,028 (52.3 %)	40,560 (52.3 %)	1.000	1	
	Male	1,848 (47.7 %)	36,960 (47.7 %)	1.000	1	
Age at index (years)		56.3 ± 9.4	56.3 ± 9.6	0.990	1.02 [0.95 to 1.10]	0.000
Age category	**40-49**	1,100 (28.4 %)	21,624 (27.9 %)	0.509	0.92 [0.86 to 0.99]	
	50-59	1,325 (34.2 %)	27,903 (36.0 %)	0.023	1.11 [1.03 to 1.19]	
	60-69	1,111 (28.7 %)	20,594 (26.6 %)	0.004	1.02 [0.91 to 1.15]	
	70-79	326 (8.41 %)	6,389 (8.24 %)	0.697	0.27 [0.15 to 0.46]	
	80-89	14 (0.36 %)	1,010 (1.30 %)	<0.001	1.02 [0.95 to 1.10]	
Year of index date	mean ± SD	2015 ± 4	2015 ± 4	1.000		0.000
	median [IQR]	2016 [2013 ; 2018]	2016 [2013 ; 2018]			0.000
Weight (kg)		76.3 ± 15.3	77.3 ± 16.5	<0.001		-0.060
Height (cm)		168 ± 9	167 ± 10	<0.001		0.079
Body Mass Index (kg/m^2)		27.0 ± 4.5	27.5 ± 5.2	<0.001		-0.114
BP systolic (mmHg)		134 ± 20	133 ± 17	0.104		0.019
BP diastolic (mmHg)		76.8 ± 10.1	77.5 ± 9.0	<0.001		-0.079
Smoking status	Non-smoker	3,168 (82.8 %)	56,248 (75.3 %)	<0.001	1.58 [1.45 to 1.73]	
	Past smoker	105 (2.74 %)	2,181 (2.92 %)	0.587	0.94 [0.76 to 1.15]	
	Smoker	553 (14.5 %)	16,301 (21.8 %)	<0.001	0.61 [0.55 to 0.66]	
Ethnic sector	Arab	88 (2.27 %)	1,760 (2.27 %)	1.000	1	
	General	3,591 (92.7 %)	71,820 (92.7 %)	1.000	1	
	Jewish ultra-orthodox	197 (5.1 %)	3,940 (5.1 %)	1.000	1	

852
Baseline demographic and clinical characteristics of Leumit Health Services (LHS) patients exposed to
atovaquone-proguanil or mefloquine (cases) compared with matched controls. Matching was performed
on birth year, sex, ethnic sector, and socioeconomic status (SES) category. Reported values reflect
characteristics at the index date (first prescription for cases; assigned index date for controls).
Counts and percentages represent the distribution of categorical variables in cases and controls at
baseline. Odds ratios (OR) with 95% confidence intervals (CI) are shown for categorical comparisons,
alongside p-values from Fisher's exact test. Continuous variables are presented as mean ± standard
deviation (SD), with standardized mean differences (SMD; Cohen's d) provided as effect size estimates.
Abbreviations: BP, blood pressure; BMI, body mass index.
862

Table 3. Demographic and clinical characteristics of the matched TriNetX cohorts for atovaquone-proguanil, mefloquine, and nirmatrelvir-ritonavir exposure (Analysis C).

			Atovaquone-proguanil	Mefloquine	Nirmatrelvir-ritonavir
N			24,498 / 24,498	3,400 / 3,400	124,681 / 124,681
Age at Index			69.0±5.8 / 69.0±5.9	67.6±6.2 / 67.7±6.3	74.9±5.2 / 75.0±5.5
Current age*			76.7±4.8 / 76.8±5.0	76.8±5.0 / 76.1±4.9	77.0±5.1 / 80.3±5.4
Sex		Female	55.0% / 55.0%	52.0% / 52.5%	57.7% / 58.1%
		Male	45.0% / 45.0%	48.0% / 47.5%	42.3% / 41.9%
Race/Ethnicity		White	82.8% / 83.3%	55.4% / 56.2%	86.7% / 83.5%
		Black or African American	5.3% / 5.2%	15.7% / 15.4%	4.7% / 4.8%
		Hispanic or Latino	1.2% / 1.1%	1.3% / 1.0%	2.8% / 2.7%
		Not Hispanic or Latino	83.8% / 79.7%	82.5% / 78.0%	73.1% / 75.7%
		Asian	4.5% / 4.2%	13.4% / 13.3%	3.4% / 4.1%
		Other Race	1.6% / 1.8%	4.4% / 3.5%	1.9% / 2.5%
Nicotine dependence			3.5% / 3.3%	3.1% / 2.7%	7.9% / 7.5%
Diabetes mellitus			14.0% / 13.6%	22.3% / 21.9%	26.0% / 25.4%
Overweight or obesity (diagnosis)			14.4% / 14.3%	13.0% / 13.4%	26.8% / 25.6%
Hemoglobin A1c (%)			5.9±0.9 / 5.9±1.1	6.3±1.1 / 6.2±1.2	6.0±1.0 / 6.0±1.0
Hemoglobin A1c range		0-5.7 %	25.6% / 25.4%	15.9% / 15.7%	35.9% / 33.7%
		5.7-6.5 %	25.5% / 24.9%	27.1% / 26.5%	38.7% / 35.2%
BMI (kg/m^2)			26.8±4.8 / 26.8±4.9	27.4±4.9 / 27.2±5.1	28.2±5.9 / 28.2±5.8
BMI ranges (kg/m^2)		0-25	52.1% / 52.5%	46.4% / 47.0%	45.7% / 48.6%
		25-30	57.9% / 57.7%	57.4% / 57.8%	60.7% / 61.6%
		30-35	27.9% / 27.9%	30.5% / 30.1%	39.9% / 39.9%
		35-40	9.4% / 9.1%	10.0% / 9.4%	18.6% / 17.9%
		40-	3.4% / 3.2%	4.2% / 3.8%	8.7% / 8.6%

Baseline demographic and clinical characteristics of patients exposed to atovaquone-proguanil, mefloquine, or nirmatrelvir-ritonavir and their propensity score-matched controls in the TriNetX network. Matching was performed on age, sex, race, ethnicity, smoking status, diabetes diagnosis, BMI, and HbA1c levels at baseline. Reported values reflect characteristics at the index date (first prescription for exposed patients; matched ambulatory visit for controls).
Values are presented as mean ± standard deviation (SD) for continuous variables and as percentages for categorical variables. For each variable, values before the slash correspond to the medication-exposed group and values after the slash correspond to the matched control group. Variables include demographics, comorbidities, and metabolic parameters relevant to baseline risk stratification across the three exposure cohorts. SMD<0.1 for all matched variables.
* In TriNetX, current age is calculated from birth irrespective of mortality. Equivalent current age between arms therefore confirms calendar alignment of index dates.

Figure 1. Design of the analyses performed to identify and validate medications associated with increased longevity and decreased age-related morbidity.

Figure 2. Cumulative mortality and incidence of major health outcomes in patients treated with antiprotozoals versus matched controls in LHS (Analysis B).

Kaplan-Meier curves showing cumulative incidence of major health outcomes among Leumit Health Services (LHS) patients exposed to mefloquine or atovaquone-proguanil (red) compared with matched

controls (blue). Hazard ratios (HR), 95% confidence intervals (CI), and p-values were estimated from Cox proportional hazards models. Follow-up was censored at the date of death or last recorded visit, whichever occurred later, and individuals with a diagnosis of the outcome prior to the index date were excluded. Shaded areas represent 95% CI.

Panel labels: A, all-cause mortality; B, dementia; C, diabetes mellitus; D, congestive heart failure (CHF); E, myocardial infarction; F, hepatic failure; G, chronic obstructive pulmonary disease (COPD); H, gastrointestinal (GI) malignancy; I, lung malignancy; J, hearing loss; K, dry eye; L, lichen planus.

Figure 3. Forest plot of selected health outcomes in patients treated with atovaquone-proguanil or mefloquine vs. matched controls in LHS (Analysis B).

Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality and selected age-related conditions among patients treated with mefloquine or atovaquone-proguanil, compared with matched controls in Leumit Health Services (LHS). Outcomes were estimated using Cox proportional hazards models, with follow-up censored at the date of death or last recorded visit, whichever occurred later. Individuals with a diagnosis of the respective condition prior to the index date were excluded. Horizontal bars indicate 95% CIs; values to the left of 1 indicate reduced risk, and those to the right indicate increased risk. Protective associations were identified for mortality, dementia, diabetes, cardiovascular events, hepatic failure, COPD, and several malignancies. Conversely, increased risks were observed for hearing loss, dry eye, and lichen planus.

Figure 4. Cumulative incidence of mortality and age-related health outcomes following antiprotozoal exposure in TriNetX cohorts (Analysis C).

Cumulative incidence curves comparing patients treated with atovaquone-proguanil (left), mefloquine (middle), and nirmatrelvir-ritonavir (right) versus propensity score-matched controls in the TriNetX network. Outcomes include all-cause mortality and selected age-related conditions identified in the LHS cohort, with follow-up extending up to eight years for atovaquone-proguanil and mefloquine and up to

three years for nirmatrelvir-ritonavir. Individuals with prior diagnoses of the respective outcomes at baseline were excluded from each analysis. Hazard ratios (HR), 95% confidence intervals (CI), and p-values were estimated using Cox proportional hazards models. Associations included consistent reductions in mortality and morbidity across multiple outcomes, while increased risks were identified for certain adverse events, including hearing loss and ophthalmic conditions.